Could a common laxative soothe gut inflammation in cystic fibrosis?

NCT ID NCT04458129

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This phase 2 trial investigates whether polyethylene glycol (a laxative) can reduce intestinal inflammation in children with cystic fibrosis. The study includes children aged 4 to 17 with cystic fibrosis and pancreatic insufficiency who have elevated fecal calprotectin (a marker of gut inflammation). Participants take polyethylene glycol daily for 3 months, and the main goal is to see if their calprotectin levels drop below a certain threshold, indicating reduced inflammation.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
polyethylene glycol (Macrogol 4000)
What this could lead to
If it works, this could offer a simple, non-drug way to manage gut inflammation in children with cystic fibrosis, improving digestive health.
What could go wrong
This is a small, early-phase trial with only 23 participants. The treatment may not reduce inflammation enough, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.